Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The Next Generation of Research and Care Annual Parkinson symposium April 8, 2017 Outline • Next generation research • Next generation care 2 Outline • Next generation research • Next generation care 3 Health care needs a new class of measurements that can provide high frequency data Social Physics # measurements per person per minute Current clinical trials * Framingham Heart Study Duration of observation Source: Modified from Pentland A. Social Physics: How Social Networks Can Make Us Smarter. New York, Penguin Books, 2015. 4 In 2015 Apple announced the release of smartphone applications for medical research mPower smartphone application for Parkinson disease 5 These apps can detect responses from medications Tapping frequency in individual with Parkinson disease before and after medication After levodopa Before levodopa Source: Sage Bionetworks 6 Early analyses suggest mPower assessments correlate with standard clinical assessments… MDS-UPDRS Part 3, motor exam score (clinician rated) Correlation between mPower’s finger tapping and MDS-UPDRS part 3 (motor) scores Number of taps 7 You can become a research partner and help us better manage the symptoms of PD together If you are interested in joining our team’s study, please contact our study coordinator – Molly Elson: Phone: (585) 276-6825 Email: [email protected] 8 Recently, with your help, we conducted a pilot study to assess wearable sensors for multiple neurological disorders MC10 BioStampRC Sensor-MD Overview: • • • Source: http://www.mc10inc.com/our-products/biostamprc We enrolled 61 participants • 19 with Parkinson disease • 15 with Huntington disease • 5 with prodromal Huntington disease • 22 without a movement disorder Participants wore 5 sensors on their chest and limbs Aims of the study: • Assess feasibility of data collection • Compare sensor data to standard clinical assessments • Develop algorithms to characterize abnormal movements • Assess response to medication • Detect and quantify previously unmeasured symptoms 9 These sensors can detect symptomatic changes due to medication Spectrogram of energy distribution as a function of frequency for a PD participant with rest tremor Harmonics Harmonics Parkinson disease tremor frequency signature Source: Sensor-MD study (confidential) 10 In addition, they can also objectively capture lifestyle attributes that reflect previously unknown symptoms Proportion of time in each state Proportion of day individuals spend lying down, sitting, standing, and walking Stand/Sit Stand/Sit Walking Walking Standing Standing Stand/Sit Walking Standing Sitting Sitting Preliminary Stand/Sit Walking Standing Sitting Sitting Lying down Lying down Control (n=20) Mean age: 58 Parkinson Disease (n=16) Mean age: 68 Source: Sensor-MD study (confidential) Lying down Huntington disease (n=15) Mean age: 55 Lying down Prodromal Huntington disease (n=5) 11 Mean age: 38 In addition to our smartphone and wearable sensor studies, we have other trials currently enrolling Buspirone in PD – Dr. Ruth Schneider • • • Study testing tolerability of an anxiety medication called buspirone (Buspar). Seeking individuals who have both Parkinson disease and anxiety and do not anticipate making changes to their Parkinson, anxiety or depression medications in the next 3 months Seeking individuals who do not have: liver or kidney impairment, drug/alcohol dependence, previous exposure to buspirone Contact Julia Iourinets at 585-341-7433 or [email protected] for more info TOZ-PD – Dr. Rich Barbano • • • Study testing the efficacy of a medication called tozadenant Seeking individuals who are experiencing end-ofdose wearing off while taking levodopa at least 4 times per day in addition to another PD medication Seeking individuals who have been diagnosed at least 3 years ago Contact Ashley Owens at 585-341-7593 or [email protected] for more info Outline • Next generation research • Next generation care 13 Current care for PD has some flaws How different care models meet the needs of individuals with Parkinson's disease Feature Individuals with Parkinson’s disease Current care models Home-based care Location Primarily suburban and rural areas Primarily urban centers Where the individual is located Driving Impaired ability Usually requires driving Little or no driving required Mobility Limited Generally required to access care Not required to access care Cognition Frequently impaired Often demanding to navigate Less demanding to receive Disease course Progressive Least accessible for those with the most advanced disease Accessible to those with greatest need Caregivers Burdened Increases the burden Can reduce the burden Source: Mov Disord. 2016 Sep;31(9) We recently completed the largest national randomized controlled trial of telemedicine into the home Randomized controlled trials of telemedicine providing care into a patient’s home Study (year) Condition N Sites Findings National randomized controlled trial of virtual house calls for individuals with Parkinson disease (Connect.Parkinson) (2016) Parkinson disease 195 18 • Providing specialty care into the homes of individuals with Parkinson disease was feasible • Not more efficacious than usual in-person care • Satisfaction was higher in the telemedicine group Randomized controlled clinical trial of “virtual house calls” for Parkinson disease. (2013) Parkinson disease 20 2 • Virtual house calls were feasible • As effective as in-person care A randomised trial of a remote home support programme for infants with major congenital heart disease. (2012) Congenital heart defects 83 2 • Clinicians were more confident in treating patients in video visits vs. telephone • Parents were satisfied with video visits • Healthcare resource utilization was lower in telemedicine group A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study (2011) HIV 83 2 • Satisfaction with Virtual Hospital was high • Clinical outcomes were similar for both groups Home videoconferencing for patients with severe congenital heart disease following discharge (2008) Severe congenital heart disease 30 1 • Videoconferencing decreased anxiety levels compared to telephone and allowed better clinical information Functional and Clinical Outcomes of Telemedicine in Patients With Spinal Cord Injury (2008) Spinal cord injuries 137 4 • Telemedicine patients at one out of four sites had statistically significant better functional improvement • Satisfaction was high higher in the telemedicine group Telemedicine improved diabetic management (2000) Type II diabetes 28 1 • Some clinical outcomes improved significantly more in the telemedicine group • Quality of life was unchanged Sources: Connect.Parkinson, JAMA Neurol. 2013;70(5):565–570., Heart. 2012;98(20):1523–1528., Congenit Heart Dis. 2008;3(5):317–324., PLoS One. 2011;6(1):e14515., Mil Med. 2000;165(8):579–584., Arch Phys Med Rehabil.2008;89(12):2332–2341. 15 Connect.Parkinson was conducted nationally In collaboration with: Source: Connect.Parkinson study 16 Over 11,000 individuals from 80 countries and 50 states visited the study website Map of visitors to Connect.Parkinson website Source: Connect.Parkinson study 17 Ultimately, 195 participants were randomized Map of Connect.Parkinson participants (n = 195) On average, participants were 66 years old, were 47% female, had a disease duration of 8 years, and 97% used internet at home 18 Virtual house calls are feasible and valuable but not more (or less) effective than traditional care Results from the Connect.Parkinson study Feasibility • Out of the 97 individuals randomized to receive virtual house calls, 95 completed at least one virtual house call (98%) • Of the total 388 virtual house calls, 91% were completed as scheduled • Evaluated using the Parkinson Disease Questionnaire 39 (PDQ-39) Quality of life • Between the two groups there was no significant change in the PDQ39 as the mean difference was 0.3 points (p = 0.78) Quality of care Value • Between the two groups there was no significant change in the quality of care as the mean difference was 0.0 points (p = 0.79) • Patients saved a median of 88 minutes per visit (p < 0.0001) • Patients saved a median of 38 miles round-trip per visit (p < 0.0001) Source: Connect.Parkinson study. 19 Patients receiving virtual house calls indicated a greater improvement in their PD overall Patient Global Impression of Change 45 p = 0.0039 40 Percentage of participants 35 30 25 20 15 10 5 0 No change (or condition has gotten worse) Almost the same, A little better, but no Somewhat better, but hardly any change at noticeable change the change has not all made any real difference Virtual house calls (n = 90) Source: Connect.Parkinson study Moderately better, and a slight but noticeable change Better, and a definite A great deal better, improvement that has and a considerable made a real and improvement that has worthwhile difference made all the difference Usual care (n = 89) 20 Patients were very satisfied with virtual house calls Patient satisfaction with virtual house calls (n = 320) Very Satisfied Satisfied Neutral Unsatisfied Very Unsatisfied Technical quality of connection Care Convenience Comfort Overall 0% 20% 40% 60% 80% 100% Percent of patients 21 Source: Connect.Parkinson study Patients found care, convenience, and comfort in virtual house calls Selected patient feedback Care Convenience • • • “Excellent, just wish these visits could continue.” “Excellent help accompanied by warmth, compassion and expertise.” “The regular intervals of seeing my neurologist through a virtual visit allowed my neurologist to treat more of my symptoms that emerged gradually... I do not have that kind of awareness of how my PD is gradually changing in once-a-year visit with my regular neurologist.” • “As my wife and I live a long way from the nearest neurologist, this technology is a blessing.” “To get to be seen by a PD specialist I would have to drive 175 miles from my doorstep to the specialist’s office or farther, 309 miles.” • • Comfort Source: Connect.Parkinson study • “I find it easier to be more comfortable expressing my PD via a remote device than I do during a face-to-face visit.” “I really felt comfortable and did not feel like I was missing anything crucial by not being there in person. It's so nice to not have to get in the car to go to an appointment!!” 22 Overall, patients preferred virtual house calls to in-person visits on a variety of aspects Participants relative preference of virtual house calls (n = 68) Favors virtual house calls Strongly Agree Agree Neutral Disagree Strongly Disagree Favors in person visits Better personal connection Better care More convenient More comfortable Prefer virtual visits overall 0% Source: Connect.Parkinson study 20% 40% 60% 80% 100% 23 Telemedicine is poised for exponential growth, which is occurring in Canada… Number of telemedicine visits by Ontario Telemedicine Network, 2009-2014 250,000 200,000 150,000 Urban 100,000 50,000 Rural 2009 2010 Source: O’Gorman LD et al. Telemedicine and e-Health 2016;22:473-9 2011 2012 2013 2014 24 …and beginning to do so in the US Projected number of office visits in the U.S., 2015 – 2025 25 We are now offering any New Yorker with Parkinson disease the ability to receive care for free Who: Any New Yorker with Parkinson disease What: Multidisciplinary care + optional use of smartphone to track disease When: Now Where: New York state, especially the 9 counties surrounding Rochester Why: To provide PD care to residents of New York state, especially the underserved How much: Free Supported by: Greater Rochester Health Foundation & the Edmond J. Safra Foundation Visit our booth here Visit www.pdcny.org or Call 1-844-77-PDCNY (1-844-777-3269) 26